The sharpest verdict: both pipeline assets rest on early or anecdotal evidence while nine registrational Phase III trials consume cash at a rate that implies a 2-3 year runway — and no Phase 3 readout has been reported for either program. Olverembatinib's strongest documented clinical event is a single case report of post-second allogeneic HSCT maintenance in a T315I-mutated blast crisis patient who achieved major molecular response after induction; this is case series/compassionate-use evidence, the lowest tier, and attribution of benefit is confounded by concurrent induction therapy and the transplant itself. [1] The asset's guideline inclusion in the 2025 Chinese CML recommendations alongside ponatinib and asciminib is a meaningful commercial signal in China, but it does not substitute for controlled efficacy data. [2] Ponatinib — a true mechanistic peer as a third-generation BCR::ABL1 TKI with T315I activity, approved on single-arm Phase 2 data — provides the most usable regulatory precedent, establishing that randomized Phase 3 data may not be required for this population. However, ponatinib's post-approval trajectory of cardiovascular toxicity findings, temporary suspension, and label restriction creates an unavoidable safety precedent: olverembatinib's cardiovascular profile is entirely uncharacterized in the available inputs. [3] Asciminib, though listed alongside olverembatinib in the same guideline, binds the ABL myristoyl pocket rather than the ATP-binding site and is mechanistically distinct; it cannot serve as a clean precedent. [3] For lisaftoclax, Phase 1 single-arm data (NCT03913949, n=51 Chinese patients) showed an ORR of 71.4% and CR of 28.6% in relapsed/refractory CLL/SLL, with a median PFS of 18.6 months and no dose-limiting toxicity or tumor lysis syndrome — a signal comparable in magnitude to venetoclax's early development. [4] Venetoclax is the mechanistically matched peer and precedent (BCL-2 inhibitor, CLL/SLL), but it required Phase 3 RCT data for full approval and broad payer acceptance, and its market access was unlocked by combination therapy datasets that lisaftoclax has not yet produced. [4] Critically, the Phase 1 trial excluded patients with prior BCL-2 inhibitor resistance, meaning the growing venetoclax-exposed relapsed/refractory population is entirely unaddressed by current data. [4] No payer cost-effectiveness or ICER data exists for either asset. With cash at US$279.4 million, a net loss of US$120.4 million in H1 2026 alone, and nine Phase III trials running, financing risk is the sharpest near-term threat.
Olverembatinib's controlled efficacy data is unreported; lisaftoclax's strongest data is a single-arm Phase 1 trial (NCT03913949, n=51) with no randomized comparator, no Phase 3 readout, and a population that excluded prior BCL-2 inhibitor-exposed patients — limiting generalizability to the evolving real-world CLL landscape. [4]
| Indication | Chronic Myeloid Leukemia |
| Drug | Olverembatinib |
| Mechanism of Action | BCR-ABL1 TKI |
| Company | Ascentage Pharma Group International |
| Trial Phase | Phase III |
| Trial Acronym | POLARIS-1 |
| Category | Clinical Trial Event |
| Sub Category | Patient Enrollment Milestone |
| Therapeutic Area | Oncology |
| H1 2026 Revenue | US$44.5 million |
| Revenue Growth (YoY) | 29.3% |
| H1 2026 Net Loss | US$120.4 million |
| Cash and Bank Balances (June 30, 2026) | US$279.4 million |
| Registrational Phase III Trials Ongoing | Nine |
| Executive Appointments | Chief Business Officer, Chief Commercial Officer |
| Olverembatinib Formulary Reach | 879 DTP pharmacies and hospitals |
| Lisaftoclax Formulary Reach | 415 DTP pharmacies and hospitals |
| Regulatory Agencies | FDA, EMA |
| Approved Region | China |
Ascentage Pharma Reports Strong H1 2026 Revenue Growth and Pipeline Progress
Ascentage Pharma reported a 29% year-over-year increase in revenue to US$44.5 million for the first half of 2026, primarily driven by product sales. The company also expanded its executive leadership with new Chief Business Officer and Chief Commercial Officer appointments. Key clinical programs for Olverembatinib and Lisaftoclax are advancing, with nine registrational Phase III trials ongoing globally, including four cleared by FDA and EMA. The company's cash and bank balances decreased to US$279.4 million due to increased R&D expenses, leading to a net loss of US$120.4 million for the period.
- Financial Performance: Ascentage Pharma's revenue for H1 2026 grew by 29.3% to US$44.5 million (RMB302.2 million) compared to H1 2025, mainly due to a 32.6% increase in product sales to US$41.6 million. However, the company reported a net loss of US$120.4 million, an increase from US$82.5 million in H1 2025, primarily due to significant increases in R&D and selling/distribution expenses, and a decrease in cash balances to US$279.4 million.
- Clinical Pipeline Advancement: The company is actively progressing nine registrational Phase III clinical trials worldwide, with four cleared by the FDA and EMA. This includes trials for Olverembatinib in CML, Ph+ ALL, and SDH-deficient GIST, and for Lisaftoclax in HR-MDS, AML, and CLL/SLL, demonstrating a broad and active clinical development strategy across multiple oncology indications, highlighting global expansion.
- Commercial and Strategic Growth: Ascentage Pharma strengthened its commercial capabilities by appointing Dr. Faiçal Miyara as Chief Business Officer and Mr. Jim Ziegler as Chief Commercial Officer. Commercial reach for Olverembatinib expanded, with DTP pharmacies and hospitals on formulary increasing by 12% to 879, and hospital formulary inclusion growing by 34% to 394. Lisaftoclax also saw its formulary reach 415 DTP pharmacies and hospitals, indicating strong market penetration efforts.
POLARIS-2: Advancing Olverembatinib in Chronic Myeloid Leukemia
The clinical development landscape for CML spans multiple trial designs — from randomized head-to-head comparisons to discontinuation studies and meta-analytic validations — each contributing distinct evidence on efficacy benchmarks, molecular response thresholds, and long-term survivorship. Together, these trials define the evidentiary framework against which emerging agents such as olverembatinib are being evaluated. The table below summarizes the key design parameters and endpoints across these pivotal studies.
| Trial / Study | Design | Population | Primary Endpoint(s) | Key Secondary Endpoint | Key Results |
|---|---|---|---|---|---|
| ASC4FIRST | Phase 3 randomized trial; asciminib vs. investigator-selected TKIs (IS-TKIs), including an imatinib-specific stratum | Newly diagnosed CML-CP | Superior MMR rate vs. all IS-TKIs; superior MMR rate vs. imatinib (imatinib stratum) | MMR rate at Week 96 | MMR at Week 96: 74.1% (asciminib) vs. 52.0% (IS-TKIs); 76.2% vs. 47.1% in imatinib stratum; 72.0% vs. 56.9% vs. 2G-TKIs |
| D-FREE Study | Treatment discontinuation study; dasatinib induction followed by TKI cessation | Newly diagnosed CML-CP achieving MR4.5 (BCR-ABL1 ≤0.0032% IS) maintained for ≥1 year; dasatinib induction ≤2 years | Molecular relapse-free survival (loss of MMR confirmed once, or loss of MR4 on 2 consecutive assessments) | — | 60/123 (48.8%) reached MR4.5; estimated molecular relapse-free survival 16.7% at 12 months; study terminated early per safety monitoring criteria |
| TFR Meta-Analysis | Systematic review and meta-analysis of 12 TKI stopping studies (N=1,699) | CML patients enrolled in TKI discontinuation trials | TFR rate at 24 months post-TKI cessation | Impact of molecular stopping criteria (MR4.5+ vs. MR4.0) and DMR duration (≥24 vs. 12–18 months) | Overall mean TFR at 24 months: 55% (95% CI 0.51–0.58); MR4.5+ criteria: 57.2% vs. 50.5% (MR4.0); ≥24-month DMR: 60.2% vs. 49.9% |
| Surrogate Endpoint Validation | Systematic review and meta-analysis assessing surrogate validity of early molecular responses | CML patients receiving first-line imatinib, dasatinib, or nilotinib | Validation of CCyR and MMR at 12 months as surrogates for overall survival | — | Predicted mean survival 21–23 years across imatinib, dasatinib, and nilotinib; CCyR and MMR at 12 months supported as surrogate endpoints for OS |
Addressing Unmet Needs in Resistant and Intolerant CML
Despite the transformative impact of tyrosine kinase inhibitors (TKIs) on CML management, significant clinical challenges persist that limit long-term outcomes for a meaningful subset of patients. Resistance, treatment-emergent toxicities, and the persistence of leukemic stem cells continue to represent critical unmet needs, collectively preventing CML patients from achieving normalized overall survival.
BCR-ABL–Dependent Resistance: Approximately 20–25% of patients initially treated with imatinib require alternative therapy due to drug resistance, most commonly driven by point mutations within the Abl kinase domain that impair TKI binding. The T315I gatekeeper mutation is particularly intractable, remaining refractory to second-generation TKIs including dasatinib, nilotinib, bosutinib, and INNO-406.
BCR-ABL–Independent Resistance via Leukemic Stem Cell Persistence: Resistance also emerges through kinase-independent mechanisms, primarily driven by the persistence of leukemia stem cells (LSCs) in the bone marrow niche. LSCs reside in a quiescent state that renders them largely insensitive to TKI-mediated killing. The niche microenvironment further sustains LSC survival by promoting cell cycle arrest, generating anti-apoptotic signals, suppressing immune function, and facilitating metabolic reprogramming — effects that are both niche-driven and actively reinforced by LSC-secreted cytokines and costimulatory molecules.
Cardiovascular Toxicity: Long-term TKI use carries a substantial cardiovascular burden. Nilotinib is associated with elevated incidence rate ratios for acute myocardial infarction (IRR 2.9; 95% CI 1.5–5.6) and chronic ischemic heart disease (IRR 2.2; 95% CI 1.2–3.9), while ponatinib and nilotinib are both implicated in arterial occlusive events — including ischemic heart disease, cerebrovascular ischemia, and peripheral arterial occlusive disease. Dasatinib is associated with pulmonary hypertension.
Non-Cardiovascular Serious Adverse Events: Dasatinib carries a markedly elevated risk of pleural effusion (IRR 11.6; 95% CI 7.6–17.7) and infectious complications, including pneumonia (IRR 2.8; 95% CI 2.3–3.5) and unspecified sepsis (IRR 3.5; 95% CI 2.6–4.7). Across the TKI class, elevated incidence rate ratios have been observed for heart failure (IRR 2.6; 95% CI 2.2–3.2) and acute myocardial infarction (IRR 2.0; 95% CI 1.5–2.6), with rare renal complications — including dasatinib-induced nephrotic syndrome — also reported.
Subnormal Overall Survival Despite Deep Responses: Despite the profound improvements in disease control achieved with TKIs, overall survival in CML patients remains below population norms. The cumulative morbidity associated with long-term TKI exposure — particularly with second-generation agents — may translate into excess mortality, underscoring the gap between achieving molecular remission and restoring life expectancy to that of the general population.
Olverembatinib's Expanding Horizon: ALL and GIST Trials
Beyond its established role in chronic myeloid leukemia, olverembatinib is being evaluated across a range of oncology indications in both early- and late-phase clinical settings. The pipeline spans hematologic malignancies and solid tumors, reflecting the molecule's broader kinase inhibition profile.
Ph+ Acute Lymphoblastic Leukemia (Ph+ ALL): The POLARIS-1 phase 3 registrational trial (NCT06051409) is evaluating olverembatinib in newly diagnosed Ph+ ALL patients. Supporting this, a multicenter study assessed olverembatinib-based regimens as frontline therapy in 20 patients with de novo Ph+ ALL.
SDH-Deficient Gastrointestinal Stromal Tumors (GISTs): The POLARIS-3 phase 3 trial (NCT06640361) is investigating olverembatinib specifically in patients with succinate dehydrogenase-deficient GISTs. Earlier evidence comes from a phase 1 study (NCT03594422) that evaluated safety and antitumor activity in 66 patients with unresectable or metastatic GIST and other solid tumors, including 26 patients with TKI-failed SDH-deficient GISTs.
FLT3-ITD Mutant Acute Myeloid Leukemia (AML): At the preclinical stage, olverembatinib (HQP1351) has been assessed both as monotherapy and in combination with the BCL-2 inhibitor lisaftoclax (APG-2575) in FLT3-ITD mutant AML cell lines, evaluated across in vitro and in vivo models.
Intervention model detail: Specific intervention model designations (e.g., parallel assignment, single-group assignment, crossover) for the POLARIS-1 and POLARIS-3 trials are not available in the current literature reviewed.
Ascentage's Global Push: Tackling Resistance in Hematologic Cancers
Ascentage Pharma's recent financial update and pipeline advancements paint a clear picture of a company in a critical growth phase, strategically investing in its future despite current net losses. The focus on two key assets, Olverembatinib and Lisaftoclax, highlights a targeted approach to addressing significant unmet needs in hematologic malignancies.
Olverembatinib is emerging as a vital therapeutic option for patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who have exhausted other tyrosine kinase inhibitor (TKI) treatments. Its proven efficacy against the challenging T315I mutation, and its activity even after failure of other advanced TKIs like ponatinib and asciminib, positions it as a crucial salvage therapy. The successful global Phase 1b trial, confirming its consistent pharmacokinetic profile and strong antileukemic activity across diverse patient populations, paves the way for its broader international adoption. However, the identification of BCR-ABL-independent resistance mechanisms, such as those involving PI3K/AKT and purine metabolism pathways, suggests that ongoing research into overcoming these challenges will be essential to maximize its long-term clinical benefit.
Concurrently, Lisaftoclax is making strides as a novel BCL-2 inhibitor, particularly in relapsed or refractory chronic lymphocytic leukemia (CLL). Its ability to overcome venetoclax resistance, a significant hurdle in current treatment paradigms, offers a compelling advantage. The favorable safety profile, characterized by a low incidence of tumor lysis syndrome with a daily ramp-up schedule, further enhances its appeal. With high overall response rates observed in combination with agents like acalabrutinib, Lisaftoclax is well-positioned to become a valuable addition to the therapeutic arsenal, especially for patients with prior venetoclax exposure or resistance.
The company's commitment to advancing nine registrational Phase III trials globally, with four already cleared by major regulatory bodies, underscores a bold strategy to secure global market access. While this aggressive R&D investment has led to increased expenses and a net loss in the short term, it reflects a calculated move to build a sustainable, product-driven revenue stream. The challenge will be to manage this financial burn effectively while navigating the competitive landscapes for both Olverembatinib and Lisaftoclax, ensuring that these promising clinical advancements translate into successful commercialization and sustained growth.
Frequently Asked Questions
References
- [1] Oriana C, Martin H et al.. Complete cytogenetic response and major molecular response as surrogate outcomes for overall survival in first-line treatment of chronic myelogenous leukemia: a case study for technology appraisal on the basis of surrogate outcomes evidence. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2013 Sep-Oct. 24041359
- [2] Jiang Q, Li Z et al.. Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial. Journal of hematology & oncology. 2022 Aug 18. 35982483
- [3] Miyazaki S. [Tyrosine kinase inhibitor-associated cardiovascular adverse events in chronic myeloid leukemia]. [Rinsho ketsueki] The Japanese journal of clinical hematology. 2021. 34497188
- [4] Zhu Y, Huang J et al.. Olverembatinib treatment in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Annals of hematology. 2024 Nov. 39400743
- [5] Kantarjian H, Zhai Y et al.. Olverembatinib in chronic myeloid leukemia-Review of historical development, current status, and future research. Cancer. 2025 Apr 15. 40197896
- [6] Bansal M, Verma M. Potential therapeutic targets in chronic myeloid leukemia. Medical oncology (Northwood, London, England). 2025 Jul 17. 40676443
- [7] Dahlén T, Edgren G et al.. Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow-up of patients diagnosed 2002-2017 in a complete coverage and nationwide agnostic register study. American journal of hematology. 2022 Apr. 35015312
- [8] Tanaka R, Kimura S. Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation. Expert review of anticancer therapy. 2008 Sep. 18759691
- [9] Gora-Tybor J, Robak T. Targeted drugs in chronic myeloid leukemia. Current medicinal chemistry. 2008. 19075651
- [10] Cortes JE, Hughes TP et al.. Asciminib demonstrates superior efficacy and safety in newly diagnosed chronic myeloid leukemia in the ASC4FIRST trial. Blood. 2026 Mar 26. 41397287
- [11] Buhl Rasmussen AS, Andersen CL et al.. Therapeutic drug monitoring of imatinib - how far are we in the leukemia setting?. Expert review of clinical pharmacology. 2024 Mar. 38345044
- [12] Liu X, Wang G et al.. Preclinical development of HQP1351, a multikinase inhibitor targeting a broad spectrum of mutant KIT kinases, for the treatment of imatinib-resistant gastrointestinal stromal tumors. Cell & bioscience. 2019. 31673329
- [13] Haddad FG, Sasaki K et al.. Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors. American journal of hematology. 2022 Jul. 35357036
- [14] Sutton E, Shanmuganathan N et al.. Clinical and biological predictors of treatment-free remission in CML. Leukemia & lymphoma. 2025 Dec. 41070556
- [15] Iurlo A, Cattaneo D et al.. Second attempt to discontinue TKI after molecular relapse in patients with chronic myeloid leukemia: A real-life Italian multicenter study. Cancer. 2026 Feb 1. 41562413
- [16] ElShaer A, Almasry M et al.. Dasatinib-Induced Nephrotic Syndrome: A Case Report. Cureus. 2021 Dec. 34912656
- [17] Yoshida C, Yamaguchi H et al.. Importance of TKI treatment duration in treatment-free remission of chronic myeloid leukemia: results of the D-FREE study. International journal of hematology. 2023 May. 36739328
- [18] Jabbour E, Oehler VG et al.. Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial. JAMA oncology. 2025 Jan 1. 39570620
- [19] Loscocco F, Visani G et al.. BCR-ABL Independent Mechanisms of Resistance in Chronic Myeloid Leukemia. Frontiers in oncology. 2019. 31612105
- [20] Cayssials E, Torregrosa-Diaz J et al.. Low-dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment-free remission in chronic myeloid leukemia patients: Results of a retrospective study. Cancer. 2020 Aug 1. 32459375
Contact Us
Address
One Research Ct, Suite 450
Rockville, MD 20850
For General Inquiry
info@pienomial.com
